Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Extended thromboprophylaxis with betrixaban in acutely ill medical patients
APEX Investigators
Internal Medicine
Clinical Departments
Guy's and St Thomas' NHS Foundation Trust
Stanford University
Brigham and Women’s Hospital
University of Calgary
Portola Pharmaceuticals
Duke University
Beth Israel Deaconess Medical Center
Research output
:
Contribution to journal
›
Article
›
peer-review
394
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Extended thromboprophylaxis with betrixaban in acutely ill medical patients'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acutely Ill Patients
100%
Extended Thromboprophylaxis
100%
Betrixaban
100%
D-dimer
75%
Enoxaparin
62%
Confidence Interval
50%
Relative Risk
50%
Efficacy Outcomes
37%
Placebo
25%
Once-daily
25%
Acute Disease
25%
Major Bleeding
25%
No Significant Difference
12%
Recurrent Venous Thromboembolism
12%
Population-based Cohort
12%
Large Cohort
12%
Between-group Difference
12%
Extended Duration
12%
Thromboprophylaxis
12%
Sequential Analysis
12%
Venous Thrombosis
12%
Safety Outcomes
12%
Statistical Analysis Plan
12%
Proximal Deep Vein Thrombosis
12%
Medicine and Dentistry
Thromboprophylaxis
100%
Betrixaban
100%
D-Dimer
37%
Placebo
25%
Major Bleeding
25%
Diseases
25%
Venous Thromboembolism
12%
Deep Vein Thrombosis
12%
Phlebothrombosis
12%
Sequential Analysis
12%
Pharmacology, Toxicology and Pharmaceutical Science
Betrixaban
100%
Enoxaparin
62%
D Dimer
37%
Placebo
25%
Bleeding
25%
Diseases
25%
Venous Thromboembolism
12%
Deep Vein Thrombosis
12%
Vein Thrombosis
12%